Clinical Evidence & Cost Analysis for UK Patients
Wegovy vs Mounjaro Cost Comparison: UK Clinical Evidence
When evaluating Mounjaro vs Wegovy cost considerations, the clinical evidence from UK and international trials provides crucial context for understanding value. Wegovy's STEP trial programme demonstrates robust weight management outcomes, with the landmark STEP 1 trial showing patients achieved approximately 15% average weight loss at 68 weeks when taking Wegovy alongside diet and exercise (Wilding et al., NEJM, 2021). This evidence-based foundation supports Wegovy's NICE TA875 recommendation for weight management in appropriate patients.
Mounjaro operates through a different mechanism as a dual GIP and GLP-1 receptor agonist, while Wegovy works specifically as a GLP-1 receptor agonist. Both medications require clinical assessment and ongoing prescriber support, making the cost comparison more complex than simple price-per-pen calculations. The storage requirements also differ significantly, with Wegovy maintaining stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit.
Mounjaro vs Wegovy Cost Breakdown: EverydayMeds Pricing Structure
Our transparent Wegovy pricing structure reflects the dose escalation schedule required for this prescription-only medicine. Starting doses begin at £79.99 for 0.25mg (weeks 1-4), progressing to £94.99 for 0.5mg (weeks 5-8), £99.99 for 1mg (weeks 9-12), £139.99 for 1.7mg (weeks 13-16), and £209.99 for the 2.4mg maintenance dose from week 17 onwards. These prices include our discount codes FIRST40 for new customers and DOSE25 for returning customers, applied automatically at checkout.
Our bundle options provide convenient multi-month supplies without requiring separate orders. The Intro Trio bundle (0.25mg, 0.5mg, and 1mg) costs £299.99, covering the first 12 weeks of treatment, while the Ultimate Stability Trio provides three months of 2.4mg maintenance dosing for £649.99. When comparing Mounjaro vs Wegovy cost factors, consider that Wegovy's established NHS prescribing pathway and NICE recommendation may influence future access options through conventional healthcare routes.
Weight Loss Results: Mounjaro vs Wegovy Cost Effectiveness Evidence
Clinical trial evidence provides the foundation for evaluating weight loss results when considering Mounjaro vs Wegovy cost comparisons. The STEP programme demonstrated consistent outcomes across multiple study designs, with STEP 3 showing approximately 16% average weight loss when Wegovy was combined with intensive behavioural therapy, and STEP 5 confirming sustained results of approximately clinically studied weight loss at two years. These results occurred in patients taking Wegovy alongside a reduced-calorie diet and increased physical activity.
The SELECT cardiovascular outcomes trial added further clinical value evidence, demonstrating a 20% reduction in major cardiovascular events (HR 0.80) in patients with established cardiovascular disease. This broader health impact extends beyond weight management alone, potentially influencing long-term healthcare costs and quality of life considerations that factor into overall treatment value beyond simple medication pricing.
How Wegovy Works: Mechanism Behind the Clinical Results
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural fullness hormone produced in the intestines. This mechanism reduces appetite and promotes feelings of satiety after smaller meals, potentially reducing food cravings by working on brain appetite centres. The once-weekly FlexTouch pen injection maintains consistent medication levels, supporting sustained appetite regulation throughout the treatment period. Unlike Mounjaro's dual hormone approach targeting both GIP and GLP-1 receptors, Wegovy's focused GLP-1 activity has extensive clinical validation across multiple patient populations. This established mechanism underlies the weight management outcomes observed in clinical trials when patients follow the complete treatment protocol including dietary modifications and exercise increases.
Ordering Process: Mounjaro vs Wegovy Cost and Access Pathway
EverydayMeds streamlines access to Wegovy through our comprehensive online service, registered with the General Pharmaceutical Council (#9012878). The process begins with a 3-minute online clinical assessment covering medical history, current medications, and weight management goals. Our qualified prescribers review applications within standard 3 working days, or express 24-hour service for urgent requirements. Once approved, next-day delivery ensures medication arrives via temperature-controlled cold-chain logistics, maintaining the 2-8°C storage requirements until it reaches your door. This efficient pathway removes common barriers to accessing prescription-only weight management medications while maintaining full clinical oversight. Payment processing is secure and discrete, with all pricing inclusive of clinical review, prescription fees, and delivery costs.
Storage and Practical Considerations: Wegovy vs Mounjaro Cost Benefits
Storage flexibility represents a significant practical advantage when comparing Mounjaro vs Wegovy cost considerations beyond purchase price. Wegovy maintains effectiveness for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This extended stability supports travel, reduces waste from storage accidents, and provides flexibility for patients with varying schedules. The FlexTouch pen design requires no mixing or preparation, with dose escalation clearly marked on each pen strength. Dose progression follows a mandatory schedule starting with 0.25mg for weeks 1-4, advancing through 0.5mg, 1mg, and 1.7mg phases before reaching the 2.4mg maintenance dose, ensuring tolerance while optimising effectiveness.
UK Weight Loss Results: Real-World Evidence Beyond Mounjaro vs Wegovy Cost
Real-world evidence from UK prescribing supports the clinical trial outcomes, with specialist weight management services reporting consistent patient responses when Wegovy is prescribed within NICE guidelines. The requirement for BMI ≥30, or BMI ≥27 with weight-related comorbidities, ensures appropriate patient selection that aligns with trial populations. NHS specialist services typically provide the intensive behavioural support that enhanced outcomes in STEP 3, demonstrating how comprehensive care approaches optimise results regardless of whether patients access Wegovy through NHS or private routes.
Long-term sustainability requires ongoing support, as demonstrated in STEP extension studies where patients regained approximately two-thirds of lost weight within one year of stopping treatment. This evidence emphasises that weight management represents a long-term commitment rather than a short-term intervention, influencing the true cost-effectiveness calculation when comparing different treatment options including both Wegovy and Mounjaro approaches.
Making Your Decision: Wegovy Access Through EverydayMeds
Both Wegovy and Mounjaro are available from EverydayMeds, and your prescriber can help determine which option aligns with your medical history, lifestyle factors, and treatment goals. Our clinical team, registered under GPhC #9012878, provides ongoing support throughout treatment, monitoring progress and adjusting approaches as needed. New customers can apply discount code FIRST40 at checkout, while returning customers use DOSE25, with all pricing transparent and inclusive of clinical oversight costs. Start your clinical assessment today at https://everydaymeds.co.uk/collections/wegovy to explore whether Wegovy represents the right choice for your weight management journey. Remember that successful outcomes require commitment to dietary changes and increased physical activity alongside medication, regardless of which treatment option you and your prescriber select.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
